Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 148

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 148
---
,     
 license, sub-license, or other disposition of all or a material portion of the assets of Aadi or any of its subsidiaries).                                                                                                                        |

Pursuant to the Support Agreements, the Support Agreement Stockholders have agreed not to, until the termination of the Support Agreements and subject to certain exceptions in the Support Agreements, (1) enter into any voting agreement or voting trust with respect to any of our shares of common stock, (2) grant a proxy, consent or power of attorney with respect to any of our shares of common stock, or (3) make, or in any manner participate in, directly or indirectly, a “solicitation” of “proxies” (as such terms are used in 17 CFR § 240.14a-1,et seq.) or consents from Aadi stockholders in connection with any vote of the Aadi stockholders with respect to the Divestiture Agreement, the Divestiture or the other transactions contemplated by the Divestiture Agreement. The Support Agreement Stockholders’ obligations to vote in favor of the approval of the Divestiture Agreement terminate automatically upon the earliest to occur of the termination of the Divestiture Agreement, the closing of the Divestiture or the termination of the Support Agreements. Restrictive Covenant Agreements In connection with entering into the Divestiture Agreement, certain members of the executive team of Aadi and Aadi Sub entered into Restrictive Covenant Agreements in favor of Aadi Sub and Kaken (the “Restrictive Covenant Agreements”) to be effective immediately as of the closing of the Divestiture. Pursuant to the - 96 -

Restrictive Covenant Agreements, subject to certain exceptions, such executive team members have agreed not to, from the period commencing on the date of the closing of the Divestiture and ending
on the three year anniversary thereof, research, develop, manufacture, commercialize or otherwise exploit another therapeutic product intended for the treatment of PEComa in any country or territory where the FYARRO Business has been or is currently
proposed to be conducted by Aadi and all of Aadi’s controlled affiliates.

- 97 -

THE PIPE FINANCING AND LICENSE AGREEMENT

The following is a discussion of the PIPE Financing and the License Agreement. The description of the Subscription Agreement (with respect to the PIPE Financing) and the License Agreement in this section and elsewhere in this proxy statement is qualified in its entirety by reference to the complete text of the Subscription